TRITAN BRT WHITE 11-0601 PP FR 8-6 LMS-1000

GRAY 11-040 PP FR 8-6 LMS-1000

WHITE 11-0601TPX PP FR 8-6 LMS-1000

S047.2 FEP100 J COMPOUND 11% BASO4 PP FR 8-6 LMS-1000

Geon(TM) MNE31-11-1 LAM ADH DNU Geon(TM) MNE31-13-1 S-22 STER PP FR 8-6 LMS-1000

Autoinjector Pen - Avient Application Study.mm (1) AUTO-INJECTOR APPLICATION STUDY M A T E R I A L T E C H N O L O G I E S + S E R V I C E S F O R N E X T G E N E R A T I O N D E S I G N S Avient Corporation 1 Avient Corporation 2 Innovating Design Medical innovations and plastics have gone hand-in-hand to make healthcare safer, cleaner, and more accessible for all. Requirements: Excellent clarity, scratch resistance and exceptional toughness Solution: Avient Distribution HC Portfolio: Acrylic, copolyester, PC, clarified PP Visual Identification Use colors and additives to differentiate and identify your brand, product or batch. Requirements: Strength and stiffness Solution: Nymax™ / Bergamid™ fiber reinforced materials 11.

EGG SHELL 11-0203TSX CY4000-30GF/000 FR V0 GR703 PP FR 8-6 LMS-1000

Hammerhead™ FR Flame Retardant Composite Panels Bergamid™ FR Non-Halogen Flame Retardant Formulations Maxxam™ FR Flame Retardant Formulations and Maxxam™ NHFR Non-Halogen Flame Retardant Formulations

62301SPC PACIFIC BLUE 301 AMBER IMPPC 183018COMP S&P PP FR 8-6 LMS-1000

Microsoft PowerPoint - AVNT Q4 2023 Earnings Presentation v7 AVIENT CORPORATION F O U R T H Q U A R T E R 2 0 2 3 R E S U L T S A N D 2 0 2 4 F I N A N C I A L G U I D A N C E (NYSE: AVNT) F E B R U A RY 1 4 , 2 0 2 4 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Additionally, Adjusted EPS excludes the impact of special items and amortization expense associated with intangible assets. 2 O P E N I N G R E M A R K S DR. GUIDANCE (TOTAL COMPANY) 11 $710 $719 Guidance Actual $112 $114 Guidance Actual Sales Adjusted EBITDA (in millions) $0.47 $0.52 Guidance Actual Adjusted EPS (in millions) 13.5% 15.9% 2022 2023 Results vs.